Taurine ameliorates cholesterol metabolism by stimulating bile acid production in high-cholesterol-fed rats. 2016

Shigeru Murakami, and Michiko Fujita, and Masakazu Nakamura, and Masanobu Sakono, and Shoko Nishizono, and Masao Sato, and Katsumi Imaizumi, and Mari Mori, and Nobuhiro Fukuda
Department of Bioscience, Fukui Prefectural University, Fukui.

This study was designed to investigate the effects of dietary taurine on cholesterol metabolism in high-cholesterol-fed rats. Male Sprague-Dawley rats were randomly divided into two dietary groups (n = 6 in each group): a high-cholesterol diet containing 0.5% cholesterol and 0.15% sodium cholate, and a high-cholesterol diet with 5% (w/w) taurine. The experimental diets were given for 2 weeks. Taurine supplementation reduced the serum and hepatic cholesterol levels by 37% and 32%, respectively. Faecal excretion of bile acids was significantly increased in taurine-treated rats, compared with untreated rats. Biliary bile acid concentrations were also increased by taurine. Taurine supplementation increased taurine-conjugated bile acids by 61% and decreased glycine-conjugated bile acids by 53%, resulting in a significant decrease in the glycine/taurine (G/T) ratio. Among the taurine-conjugated bile acids, cholic acid and deoxycholic acid were significantly increased. In the liver, taurine supplementation increased the mRNA expression and enzymatic activity of hepatic cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme for bile acid synthesis, by three- and two-fold, respectively. Taurine also decreased the enzymatic activity of acyl-CoA:cholesterol acyltransferase (ACAT) and microsomal triglyceride transfer protein (MTP). These observations suggest that taurine supplementation increases the synthesis and excretion of taurine-conjugated bile acids and stimulates the catabolism of cholesterol to bile acid by elevating the expression and activity of CYP7A1. This may reduce cholesterol esterification and lipoprotein assembly for very low density lipoprotein (VLDL) secretion, leading to reductions in the serum and hepatic cholesterol levels.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D002785 Sterol O-Acyltransferase An enzyme that catalyzes the formation of cholesterol esters by the direct transfer of the fatty acid group from a fatty acyl CoA derivative. This enzyme has been found in the adrenal gland, gonads, liver, intestinal mucosa, and aorta of many mammalian species. EC 2.3.1.26. Acyl-CoA-Cholesterol Acyltransferase,Cholesterol Acyltransferase,Cholesterol Esterifying Enzyme,Acyl CoA Cholesterol Acyltransferase,Acyltransferase, Acyl-CoA-Cholesterol,Acyltransferase, Cholesterol,Enzyme, Cholesterol Esterifying,Esterifying Enzyme, Cholesterol,O-Acyltransferase, Sterol,Sterol O Acyltransferase
D002790 Cholesterol 7-alpha-Hydroxylase A membrane-bound cytochrome P450 enzyme that catalyzes the 7-alpha-hydroxylation of CHOLESTEROL in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP7, converts cholesterol to 7-alpha-hydroxycholesterol which is the first and rate-limiting step in the synthesis of BILE ACIDS. CYP7,CYP7A,Cytochrome P-450 CYP7,CYP 7,CYP 7A,Cholesterol 7-alpha-Monooxygenase,Cholesterol 7alpha-Hydroxylase,Cholesterol-7-Hydroxylase,Cytochrome P450 7,Cholesterol 7 Hydroxylase,Cholesterol 7 alpha Hydroxylase,Cholesterol 7 alpha Monooxygenase,Cholesterol 7alpha Hydroxylase,Cytochrome P 450 CYP7
D002791 Cholesterol, Dietary Cholesterol present in food, especially in animal products. Dietary Cholesterol
D006903 Hydroxymethylglutaryl CoA Reductases Enzymes that catalyze the reversible reduction of alpha-carboxyl group of 3-hydroxy-3-methylglutaryl-coenzyme A to yield MEVALONIC ACID. HMG CoA Reductases,3-Hydroxy-3-methylglutaryl CoA Reductase,HMG CoA Reductase,Hydroxymethylglutaryl CoA Reductase,3 Hydroxy 3 methylglutaryl CoA Reductase,CoA Reductase, 3-Hydroxy-3-methylglutaryl,Reductase, 3-Hydroxy-3-methylglutaryl CoA
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000924 Anticholesteremic Agents Substances used to lower plasma CHOLESTEROL levels. Cholesterol Inhibitors,Hypocholesteremic Agents,Anticholesteremic Drugs,Anticholesteremics,Inhibitors, Cholesterol,Agents, Anticholesteremic,Agents, Hypocholesteremic,Drugs, Anticholesteremic
D001647 Bile Acids and Salts Steroid acids and salts. The primary bile acids are derived from cholesterol in the liver and usually conjugated with glycine or taurine. The secondary bile acids are further modified by bacteria in the intestine. They play an important role in the digestion and absorption of fat. They have also been used pharmacologically, especially in the treatment of gallstones. Bile Acid,Bile Salt,Bile Salts,Bile Acids,Acid, Bile,Acids, Bile,Salt, Bile,Salts, Bile

Related Publications

Shigeru Murakami, and Michiko Fujita, and Masakazu Nakamura, and Masanobu Sakono, and Shoko Nishizono, and Masao Sato, and Katsumi Imaizumi, and Mari Mori, and Nobuhiro Fukuda
January 2003, Advances in experimental medicine and biology,
Shigeru Murakami, and Michiko Fujita, and Masakazu Nakamura, and Masanobu Sakono, and Shoko Nishizono, and Masao Sato, and Katsumi Imaizumi, and Mari Mori, and Nobuhiro Fukuda
February 2003, Journal of nutritional science and vitaminology,
Shigeru Murakami, and Michiko Fujita, and Masakazu Nakamura, and Masanobu Sakono, and Shoko Nishizono, and Masao Sato, and Katsumi Imaizumi, and Mari Mori, and Nobuhiro Fukuda
January 2009, Advances in experimental medicine and biology,
Shigeru Murakami, and Michiko Fujita, and Masakazu Nakamura, and Masanobu Sakono, and Shoko Nishizono, and Masao Sato, and Katsumi Imaizumi, and Mari Mori, and Nobuhiro Fukuda
June 1982, Indian journal of biochemistry & biophysics,
Shigeru Murakami, and Michiko Fujita, and Masakazu Nakamura, and Masanobu Sakono, and Shoko Nishizono, and Masao Sato, and Katsumi Imaizumi, and Mari Mori, and Nobuhiro Fukuda
October 1976, Atherosclerosis,
Shigeru Murakami, and Michiko Fujita, and Masakazu Nakamura, and Masanobu Sakono, and Shoko Nishizono, and Masao Sato, and Katsumi Imaizumi, and Mari Mori, and Nobuhiro Fukuda
January 2000, Advances in experimental medicine and biology,
Shigeru Murakami, and Michiko Fujita, and Masakazu Nakamura, and Masanobu Sakono, and Shoko Nishizono, and Masao Sato, and Katsumi Imaizumi, and Mari Mori, and Nobuhiro Fukuda
July 2009, Journal of studies on alcohol and drugs,
Shigeru Murakami, and Michiko Fujita, and Masakazu Nakamura, and Masanobu Sakono, and Shoko Nishizono, and Masao Sato, and Katsumi Imaizumi, and Mari Mori, and Nobuhiro Fukuda
August 1998, Lipids,
Shigeru Murakami, and Michiko Fujita, and Masakazu Nakamura, and Masanobu Sakono, and Shoko Nishizono, and Masao Sato, and Katsumi Imaizumi, and Mari Mori, and Nobuhiro Fukuda
November 1989, The British journal of nutrition,
Shigeru Murakami, and Michiko Fujita, and Masakazu Nakamura, and Masanobu Sakono, and Shoko Nishizono, and Masao Sato, and Katsumi Imaizumi, and Mari Mori, and Nobuhiro Fukuda
January 1974, Chemical & pharmaceutical bulletin,
Copied contents to your clipboard!